The use of MDMA in conjunction with therapy before, during, and after sessions has shown promising results in treating post-traumatic stress disorder, with 78% of patients no longer qualifying for the diagnosis after three sessions. MDMA therapy is currently in phase three clinical trials with breakthrough therapy status.